Mycobacterium Abscessus Infection, NTM Lung Infection Due to MAC
Conditions
Keywords
Omadacycline, Mycobacterium abscessus, Nontuberculous mycobacterial disease, Treatment outcome, Retrospective study
Brief summary
The objective of this clinical trial is to evaluate the correlation between clinical efficacy and safety of omadacycline in the treatment of Mycobacterium abscessus infection through retrospective cohort studies. The main questions it aims to answer include: Clinical efficacy of omadacycline in populations stratified by clinical characteristics including age, gender, comorbid immune diseases, albumin level, white blood cell count and pulmonary cavity manifestations on CT.
Interventions
DRUGOmadacycline Treatment Group
Patients with Mycobacterium abscessus pulmonary disease who received omadacycline as part of their treatment regimen.All patients had culture or molecular biology confirmed Mycobacterium abscessus pulmonary disease, were aged 18 years old, had complete clinical records, and treatment duration of at least 1 month.
Sponsors
Beijing Chest Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Mycobacterium abscessus pulmonary disease confirmed by bacteriological culture or molecular biology testing; * Age 18 years or older at the time of diagnosis; * Complete clinical records available for review; * Treatment duration of at least 1 month.
Exclusion criteria
* Co-infection with other non-tuberculous mycobacterial species; * Treatment duration less than 1 month; * Missing key clinical data required for outcome assessment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of favorable treatment outcomes | From January 2014 to December 2029 | The proportion of participants achieving favorable treatment outcomes, defined as cure plus treatment completion, assessed at the end of anti-mycobacterial therapy. Cure is defined as completion of treatment with multiple consecutive negative cultures and sustained clinical improvement. Treatment completion is defined as sustained clinical improvement without proof of culture conversion due to unavailable specimens. |
Countries
China
Outcome results
None listed